6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04377945 (ClinicalTrials.gov) | April 28, 2021 | 4/5/2020 | Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components | A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components | Dyskinesias;Parkinson Disease | Drug: Part 1, JM-010 component Group A;Drug: Part 1, JM-010 component Group B;Drug: Part 1, JM-010 component Group C;Drug: Part 1, Placebo Group;Drug: Part 2, JM-010 combination Group A;Drug: Part 2, JM-010 combination Group B;Drug: Part 2, JM-010 component Group C;Drug: Part 2, Placebo Group | Bukwang Pharmaceutical | NULL | Recruiting | 18 Years | 80 Years | All | 188 | Phase 2 | United States |
| 2 | EUCTR2017-003415-19-IT (EUCTR) | 10/03/2020 | 19/05/2021 | A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable. | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010 | Parkinson’s Disease Patients With Moderate to Severe Dyskinesia MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan | Contera Pharma | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 81 | Phase 2 | France;Spain;Germany;Italy | ||
| 3 | NCT03956979 (ClinicalTrials.gov) | July 22, 2019 | 17/5/2019 | A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson's Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations of JM-010 | Dyskinesias | Drug: JM-010 group A;Drug: JM-010 group B;Drug: Placebos | Contera Pharma | Bukwang Pharmaceutical | Recruiting | 18 Years | 80 Years | All | 81 | Phase 2 | France;Germany;Italy;Spain |
| 4 | EUCTR2017-003415-19-ES (EUCTR) | 31/10/2018 | 20/08/2018 | A Clinical Study in Parkinson’s Disease Patients With Moderate to Severe Abnormal Movements to See If JM-010 is Effective and Safe/Tolerable. | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combinations Of JM-010 | Parkinson’s Disease Patients With Moderate to Severe Dyskinesia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan Product Name: JM-010 Product Code: JM-010 INN or Proposed INN: Buspirone hydrochloride INN or Proposed INN: Zolmitriptan | Contera Pharma | NULL | Not Recruiting | Female: yes Male: yes | 81 | Phase 2 | France;Spain;Germany | ||
| 5 | JPRN-JMA-IIA00385 | 01/08/2018 | 12/09/2018 | Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease | Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease | Parkinson's disease | Intervention type:DRUG. Intervention1:TACROLIMUS TABLETS, Dose form:TABLET, Route of administration:ORAL, intended dose regimen:In the early phase, the immunosuppressant is orally administered 0.03 to 0.15 mg/kg, twice a day, and the targeted blood concentration is within a range of 5-10 ng/mL as a trough value.. | Kyoto University Hospital | NULL | Completed | >=50 YEARS | <70 YEARS | BOTH | 7 | Phase 3 | Japan |
| 6 | NCT02439203 (ClinicalTrials.gov) | May 2015 | 30/4/2015 | Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia | A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010 | Parkinson's Disease;Levodopa Induced Dyskinesia (LID) | Drug: JM-010;Drug: Placebo | Bukwang Pharmaceutical | Contera Pharma ApS | Completed | 18 Years | N/A | Both | 30 | Phase 2 | South Africa |